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Aging is associated with a reduction in metabolic function,
insulin resistance, increased incidence of neurodegenerative
diseases, and memory or cognitive dysfunction. In aging fe-
males, loss of gonadal function determines the beginning of
theperiodof reducedmetabolic function.Estrogenshaveneu-
roprotective effects, but the mechanisms by which they exert
these effects remain unclear. The effects of estradiol treat-
ment on the activation of the insulin receptor substrate
(IRS)-1 signaling pathway, the interactions between estrogen
receptor (ER)- and IRS-1 and the p85 subunit of phospha-
tidylinositol-3 kinase, together with the possible effects of
estradiol treatment on glucose transporter-3 and -4 levels,
were investigated in female rats. The level of expression of
each glucose transporterwas greater in control and estradiol-
treatedgroups than in theovariectomizedgroup. Interactions
of ER46-IRS-1, ER46-p85, and p85-IRS-1, as well as IRS-1
phosphorylation, appeared to increase with estradiol treat-
ment. The results indicate that estradiol treatment improves
some aspects of neuronal homeostasis that are affected by
aging; this may indicate that estradiol has neuroprotective
effects in female rats. Additional animal studies are required
to clarify the neuroprotective role of estradiol in relation to
other important molecules involved in the IRS-1-phosphati-
dylinositol-3 kinase signaling pathway. (Endocrinology 149:
57–72, 2008)
AGING IS ASSOCIATED with a decline in metabolicfunction, and one of the main illustrations of this
metabolic decline is the development of insulin resistance.
Although the mechanism underlying the development of
insulin resistance with advanced age remains unclear, in the
case of females, loss of gonadal function seems to determine
the start of this period of metabolic decline. In addition,
insulin resistance in aging is associated with metabolic syn-
drome, which is associated with increased incidences of de-
pression, neurodegenerative diseases, and memory or cog-
nitive dysfunction (1). Therefore, the increased incidences of
neurodegenerative diseases in postmenopausal females
seem to be clinically associated with aging, loss of gonadal
function, and development of insulin resistance.
In the mammalian brain, experimental studies and clinical
observations have demonstrated the importance of estrogens
in the preservation of brain cognitive functions (2, 3), high-
lighting its protective effects against neuronal damage (4, 5).
However, it remains unclear whether estrogens can improve
some aspects of brain function during aging in females and
whether this is the mechanism by which it exerts these es-
trogen-dependent neuroprotective effects. Estrogen-related
neuroprotection can be explained not only by a classical
action mechanism (6) but also by a nonclassical action mech-
anism (4, 7), because estrogens receptors (ERs) have been
identified in extranuclear locations (cytosolic and plasma
membrane) of brain areas known to be affected during neu-
rodegenerative processes (8). At present, two ERs have been
identified, termed  (ER) and  (ER). Both are widely, but
not uniformly, distributed in the central nervous system
(CNS), and advanced age seems to affect the expression and
distribution of both. However, only ER has been implicated
in the activation of the phosphatidylinositol-3 kinase (PI3-k)
signaling pathway (8–15).
Evidence has suggested that the neuroprotective effects of
estrogens may be mediated by the activation of PI3-k sig-
naling pathways (9, 10), which are mediated by ERs. On the
other hand, as in the periphery, insulin’s action in the brain
is mediated by insulin receptor, although at higher concen-
trations, insulin also binds IGF receptors. Both receptors can
be activated, resulting in autophosphorylation and subse-
quent phosphorylation of several interacting proteins in-
cluding those of the insulin receptor substrate (IRS) family,
of which IRS-1 is the best characterized. IRS-1 induces the
activation of downstream pathways such as the regulatory
subunit (85-kDa) of PI3-k, which has a pivotal role in the
metabolic actions of insulin, including insulin-stimulated
glucose transport through the specific translocation of glu-
cose transporter-4 (Glut-4) from the intracellular pool to the
plasma membrane, and the MAPK cascades. These two sig-
naling pathways also constitute insulin receptor down-
stream cascades in the brain. Therefore, it seems possible that
ER can interact with these signaling pathways, mainly with
PI3-k and IRS-1, to promote neuroprotective effects in the
brain.
Moreover, the positive effects of estradiol could be related
to a fundamental anabolic mechanism underlying estrogen
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action on the brain. This is because estrogen treatment has
been shown to increased cerebral metabolic activity (16) and
cerebral glucose utilization (17). In this way, the expression,
regulation, and activity of brain glucose transporters have an
essential role in neuronal homeostasis because glucose is the
main energy source for the brain (18, 19). Glut-1 and Glut-3
are widely expressed in the CNS and seem to be responsible
for the most glucose uptake and utilization in the brain (20).
Glut-4 has also been found in the brain, but its abundance is
low and similar to that found in the peripheral tissues (21).
However, the presence of Glut-4, insulin-dependent glucose
transporter, in the brain could indicate that insulin directly
mediates glucose transport in the CNS (21). Several studies
have shown that brain glucose transport and utilization are
reduced in elderly patients with mild cognitive impairments
(22), and investigations into the effects of diabetes have
found similar results (23, 24). Taken together, several studies
indicate that estrogen increases glucose uptake and utiliza-
tion (25).
In an experimental model of aging using ovariectomized
rats treated with physiological doses of 17-estradiol, we
previously showed that relatively low doses of 17-estradiol
have beneficial effects on glucose homeostasis; however, the
estradiol treatment did not prevent memory and learning
impairment associated with aging (26). In the present study,
we have assessed whether estradiol treatment induced the
activation of the IRS-1 signaling pathway and affects the
interaction of ER with IRS-1 and the p85 subunit of PI3-k,
and we investigated possible effects on Glut-3 and Glut-4.
This study will improve our understanding of whether uti-
lization of estradiol can improve brain functionality during
aging. For these studies, we have selected the cortex and
diencephalon regions of the brain, because they are the areas
in which the functional interdependence of estradiol and
PI3-k has been most extensively characterized.
Materials and Methods
Animals
Virgin female Wistar rats (from the Biotery of the Faculty of Medicine,
University of Oviedo) weighing 250–280 g (age 8–10 wk) and kept under
standard conditions of temperature (23  3 C) and humidity (65  1%)
and a regular 12-h light, 12-h dark cycle (0800–2000 h) were used. The
animals were fed with a standard diet (Panlab A04), and all of them had
free access to water. All experimental manipulations were performed
between 0930 and 1230 h. All experimental procedures carried out with
animals were approved by a local veterinary committee from the Uni-
versity of Oviedo vivarium, and subsequent handling strictly followed
the European Communities Council Directive of November 24, 1986
(86/609/EEC).
Experimental design
Rats were ovariectomized through a midline incision under light
anesthesia by inhalation of halothane. Ovariectomized rats were sepa-
rated randomly into three groups: ovariectomized animals (OVX), ovari-
ectomized animals treated with 17-estradiol (E), and sham surgery
animals (intact) (C) and housed individually throughout the experiment.
After surgery, all rats began the experimental treatment exactly 1 wk
after ovariectomy to ensure a uniform time of estrogen depletion before
replacement and to recover from surgery stress. After this, the rats were
implanted sc in the posterior neck with 90-d-release 17-estradiol pellets
(25g/pellet; Innovative Research of America, Sarasota, FL) or placebos
containing no estradiol. Every 90 d, the pellets were replaced. This
dosing regimen has resulted in physiological levels of plasma estradiol
and has been shown to be neuroprotective in rats (27).
Groups (OVX, E, and C) were divided randomly into four subgroups
(seven animals per subgroup): 6, 12, 18, and 24 (according to the month
of the experimental period on which the animals were killed). Therefore,
the animals were killed when they were 8, 14, 20, and 26 months old
approximately. Moreover, 14 animals (seven OVX and seven C) were
killed 1 wk after ovariectomy (age 9–11 wk). Therefore, the animals
included in this group did not receive any treatment. These animals are
considered as OVX-0 month and C-0 month groups.
The stage of the estrous cycle in intact rats was determined by daily
examination of fresh vaginal smears. The intact animals in diestrous
phase were selected for the 0 and 6 subgroups. None of the intact rats
since month 12 of the experiment showed repetitive estrous cycles;
instead, 87.26% of them showed persistent diestrous phase.
Euglycemic insulin clamp
Clamp experiments were performed by the previously described
procedure (28), and the results were published recently (26). After the
clamp study, blood samples for the determination of 17-estradiol
plasma concentrations were collected from the jugular vein into hepa-
rinized tubes and centrifuged at 3000 rpm duforring 20 min at 4 C, and
plasma was immediately drawn off and stored frozen at 20 C until
assayed. Plasma 17-estradiol was measured by RIA using Immuchen
kits of cover tubes (ICN Biomedicals Inc., Costa Mesa, CA). The assay
sensitivity was 10 pg/ml, and the intraassay coefficient of variation was
9.45%. All samples were measured on the same day. The sample was
assayed in triplicate.
Crude extract preparation, immunoprecipitation, and
Western blot analysis
After clamp experiments, the brains were quickly removed. The cor-
tex and diencephalon were dissected and homogenized in lysis buffer
[50 mm-Tris HCl (pH 7.5), 150 mm NaCl, 1% Nonidet P-40 (Roche
Diagnostics, Indianapolis, IN), 0.05% sodium deoxycholate, sodium or-
thovanadate, 5 mm EDTA, 10% glycerol] at 4 C. The extracts were
centrifuged at 21,000  g at 4 C for 10 min, and the protein content of
the supernatant was determined by the Bradford dye-binding method
(29).
First, protein were resolved using SDS-PAGE [10% Tris (hydroxy-
methyl) aminomethane (Tris)-polyarilamide; Bio-Rad, Barcelona,
Spain]) and electrotransferred from the gel to nitrocellulose membranes
(Hybond-ECL; Amersham Pharmacia Biotech, Little Chalfont, UK) as
described by Towbin et al. (30). Nonspecific protein binding to the
nitrocellulose membranes was reduced by preincubating the filter in
blocking buffer [Tris-NaCl-Tween 20 (TNT), 7% BSA] and incubated
overnight with the primary antibodies. The antibodies against Glut-3
(sc-7582, diluted 1:1000), Glut-4 (sc-7938, diluted 1:1000), and ER (sc-
542, diluted 1:2000) were obtained from Santa Cruz Biotechnologies
(Santa Cruz, CA). Alternatively, according to Marin et al. (31), a mono-
clonal antibody directed to ER (product no. SRA-1010; Stressgen Bio-
technologies, Victoria, Canada) was also used to verify the results ob-
tained with the other anti-ER antibody. After incubation with the
primary antibody, the membranes were washed and incubated with an
antigoat antibody coupled to horseradish peroxidase (sc-2768 from
Santa Cruz, diluted 1:15,000) or an antirabbit antibody coupled to horse-
radish peroxidase (sc-2004 from Santa Cruz, diluted 1:15,000). Finally, all
membranes were stripped and probed with a monoclonal anti--actin
antibody (sc-1615 from Santa Cruz, diluted 1:2500). Immunoreactive
bands were detected using an enhanced chemiluminescence system
(ECL; Amersham). Films were analyzed using a digital scanner (Nikon
AX-110) and NIH Image 1.57 software. The density of each band was
normalized to its respective loading control (-actin) and represented as
percentage of control values (intact rats of 0 month, group C0). To
minimize interassay variations, samples from all animal groups, in each
experiment, were processed in parallel.
On the other hand, aliquots containing 500 g protein from crude
homogenate were subject to immunoprecipitation using polyclonal an-
tibodies against IRS-1 (sc-559; Santa Cruz) and the p85 subunit of PI3-k
(sc-423; Santa Cruz). Parallel immunoprecipitations were performed
using a nonimmune rabbit serum to verify the specificity of the bands
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detected by Western blotting. The immune complexes were adsorbed
and precipitated using protein G-agarose beads (sc-2002; Santa Cruz)
overnight at 4 C in a rocking platform and were washed several times
with lysis buffer, suspended in protein loading buffer [250 mm Tris-HCl
(pH 6.8), 8% SDS, 8 mm EDTA, 35% glycerol, 2.5% -mercaptoethanol,
bromophenol blue] and denatured in a boiling water bath for 5 min. The
immunoprecipitates were resolved by 10% SDS-PAGE gel and trans-
ferred to nitrocellulose membranes. Western blotting was performed as
described above using an antibody against ER (sc-542; Santa Cruz;
diluted 1:2000), against IRS-1 (sc-559; Santa Cruz), and against the p85
subunit of PI3-k (sc-423; Santa Cruz).
Statistical analysis
Data are expressed as mean  sem. Previously, we evaluated the
Gaussian distribution of each variable. After this, data were statistically
analyzed using an ANOVA design followed by between-group com-
parisons using the Tukey honestly significant difference (HSD) test. The
data for month 0 were analyzed by unpaired Student’s t test. P  0.05
was considered as significant. Statistical analysis was performed using
SPSS version 14.0.1 for Windows.
Results
The plasma 17-estradiol values obtained during the
study are shown in Fig. 1. The plasma level of estradiol was
significantly higher in the estradiol (E) and control (C)
groups than in the ovariectomized (OVX) group at all
times. In addition, plasma levels of 17-estradiol were
significantly higher in the E group than in the C group at
18 and 24 months. In the C group animals, plasma levels
of 17-estradiol increased significantly at 6 months and
then decreased significantly at 24 months. In the E group,
the estradiol level did not change significantly during the
study. A significant decrease in the estradiol level was
found in the OVX group during the first 6 months.
The effects of aging on Glut-3 and Glut-4 levels in the
cortex and diencephalon of the brain were determined. In
the cortex of intact rats, a significant increase in the level
of Glut-3 was noted over the first 12 months; the Glut-3
level then decreased significantly from 12 months until the
end of the study (Fig. 2A). A similar pattern was observed
in the OVX group, whereas in the E group, the Glut-3 level
increased significantly for the first 18 months and then
decreased significantly until the end of the study.
The amount of Glut-3 in the cortex was significantly
lower in the OVX group than in the other groups. Inter-
estingly, for the first 12 months, the Glut-3 level was higher
in the C group than in the E group, whereas at 18 and 24
months, the Glut-3 level was higher in the E group than in
the C group, although the differences were not statistically
significant.
In the C group, the pattern of Glut-3 levels in the di-
encephalon was similar to that found in the cortex (Fig.
2B). In the OVX group, a significant increase was noted
over the first 6 months, followed by a significant decrease
that lasted until the end of the study; a similar pattern was
observed in the E group.
In the diencephalon, the Glut-3 level was always sig-
nificantly higher in the C group than in the other groups.
At 6 months, the Glut-3 level was significantly higher in
the OVX group than in the E group; however, the Glut-3
level was significantly higher in the E group than in the
OVX group at all other time points.
The level of Glut-4 in the two areas of the brain studied
(Fig. 3, A and B) showed similar patterns in all groups;
there was a significant increase over the first 12 months,
followed by a significant decrease until the end of the
study. However, when the differences between the groups
at different times were examined, it was found that the
Glut-4 level was lowest in the cortex of the E group at 6
and 12 months, whereas it was lowest in the OVX group
at 18 and 24 months. Interestingly, whereas the Glut-4
level was significantly higher in the C group than in the
E group at 6 and 12 months, it was significantly higher in
the E group than in the C group at 18 and 24 months.
In the diencephalon, the differences in the level of Glut-4
between the groups were similar at 6, 18, and 24 months;
the Glut-4 level was significantly higher in the C group
than in the other groups and significantly lower in the
OVX group than in the other groups (Fig. 3B). However,
the Glut-4 level was significantly higher in the E group
than in both the other groups at 12 months.
Immunoprecipitation studies were conducted to assess
the possible interaction between ER and IRS-1. In the C
group, the pattern of the interaction between IRS-1 and
both isoforms of ER in the cortex was similar (Fig. 4A);
there was a significant increase for the first 12 months,
followed by a significant decrease toward the end of the
study. The results differed in the OVX group; the inter-
actions decreased significantly from the start to the end of
the study. In the E group, a different pattern was found for
the interaction between IRS-1 and both isoforms of ER.
Although the interaction between ER67 and IRS-1 de-
creased significantly from the start to the end of the study,
the opposite was observed with respect to the ER46-IRS-1
interaction. In the cortex, both interactions (ER67-IRS-1
and ER46-IRS-1) were significantly greater in the C group
than in the OVX and E groups. The ER67-IRS-1 interac-
tion was significantly greater in the OVX group than in the
E group, as was the ER46-IRS-1 interaction, at 6 and 12
FIG. 1. Levels of 17-estradiol of intact (C) (F(4,34)  22.23; P 
0.0001), ovariectomized (OVX) (F(4,34)  33.37; P  0.0001), and es-
tradiol-treated (E) rats (F(4,34)  2.54; P  0.13) at 0 (t(12,0.05)  5.63;
P  0.05), 6 (F(2,20)  522.3; P  0.0001), 12 (F(2,20)  740.3; P 
0.0001), 18 (F(2,20)  150.0; P  0.0001), and 24 (F(2,20)  2050.9; P 
0.0001) months of age. Values are means  SEM (n  7). Statistical
significance is based on analysis of pooled raw data using the Tukey
HSD. *, Month vs. next month; a, C vs. OVX, E; b, OVX vs. E; c, OVX
vs. C, E; d, OVX vs. C.
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FIG. 2. Glut-3 in cortex (panel A) from in-
tact (C) (F(4,34)8140.2;P0.0001),ovari-
ectomized (OVX) (F(4,34)  669.1; P 
0.0001), and estradiol-treated (E) rats
(F(4,34)1800.6;P0.0001)at0(t(12,0.05)
5.83; P  0.05), 6 (F(2,20)  21,447.3; P 
0.0001), 12 (F(2,20) 26,439.3;P 0.0001),
18 (F(2,20)  4715.5; P  0.0001), and 24
(F(2,20)9903.2;P0.0001)monthsofage
and in diencephalon (panel B) from intact
(C) (F(4,34)  9655.4; P  0.0001), ovariec-
tomized (OVX) (F(4,34)  4843.5; P 
0.0001), and estradiol-treated (E) rats
(F(4,34)1843.2;P0.0001)at0(t(12,0.05)
3.86; P  0.05), 6 (F(2,20)  22,627.2; P 
0.0001), 12 (F(2,20) 29,839.0;P 0.0001),
18 (F(2,20) 15,537.2; P 0.0001), and 24
(F(2,20) 476.6;P 0.0001)months of age.
The histogram shows the densitometric
analysis of the Western blots. Values are
means  SEM (n  7) and represented as
the percentage of control values (rats of 0
month from group C). Only significant dif-
ferences are shown. Statistical significance
is based on analysis of pooled raw data us-
ing the Tukey HSD. *, Month vs. next
month; a, C vs. OVX, E; b, OVX vs. E; c,
OVX vs. C, E; d, OVX vs. C.
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FIG. 3. Glut-4 in cortex (panel A) from
intact (C) (F(4,34)  638.8; P  0.0001),
ovariectomized (OVX) (F(4,34) 
10,792.6; P  0.0001), and estradiol-
treated (E) rats (F(4,34)  403.6; P 
0.0001) at 0 (t(12,0.05)  1.07; P  not
significant), 6 (F(2,20)  5632.4; P 
0.0001), 12 (F(2,20) 143.3; P 0.0001),
18 (F(2,20) 1056.5; P 0.0001), and 24
(F(2,20)  502.4; P  0.0001) months of
age and in diencephalon (panel B) from
intact (C) (F(4,34) 1354.2; P 0.0001),
ovariectomized (OVX) (F(4,34)  1038.1;
P  0.0001), and estradiol-treated (E)
rats (F(4,34) 38,469.8; P 0.0001) at 0
(t(12,0.05)  9.98; P  0.05), 6 (F(2,20) 
877.7; P  0.0001), 12 (F(2,20)  6351.7;
P  0.0001), 18 (F(2,20)  3391.8; P 
0.0001), and 24 (F(2,20)  3551.0; P 
0.0001) months of age. The histogram
shows the densitometric analysis of the
Western blots. Values are means SEM
(n  7) and represented as the percent-
age of control values (rats of 0 month
from group C). Only significant differ-
ences are shown. Statistical signifi-
cance is based on analysis of pooled raw
data using the TukeyHSD. *,Month vs.
next month; a, C vs. OVX, E; b, OVX vs.
E; e, E vs. OVX, C.
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months; however, at 18 and 24 months, the ER46-IRS-1
interaction was significantly greater in the E group than in
the OVX group.
In the diencephalon, the ER67-IRS-1 interaction de-
creased significantly from the start of the study to the
6-months time point in the C group, and then no further
significant changes were observed to the end of the study
(Fig. 4B). In the OVX group, there was a significant in-
crease in the ER67-IRS-1 interaction over the first 12
months, followed by a significant decrease toward the end
of the study. However, in the E group, the ER67-IRS-1
interaction decreased significantly from 6 months to the
end of the study. In contrast, the pattern for the ER46-
IRS-1 interaction showed no significant changes in the C
group for the first 12 months, and then there was a sig-
nificant decrease to 24 months. However, there was a
significant decrease in the ER46-IRS-1 interaction from
the start to the end of the study in the OVX group; in the
E group, there was a significant decrease in the ER46-
IRS-1 interaction from 6 –12 months, followed by a signif-
icant increase from 12–24 months.
The ER67-IRS-1 interaction was significantly higher in
the C group than in the others at 0 months, in the E group
than in the others at 6 months, and in the OVX group than
in the others at 12, 18, and 24 months. However, the ER46-
IRS-1 interaction was always significantly higher in the C
group than in the other two groups and always signifi-
cantly lower in the OVX group than in the other groups
(Fig. 4B).
Changes in the tyrosine phosphorylation of IRS-1 dur-
ing the aging process were also assessed. In the cortex of
the C and OVX groups, the level of IRS-1 phosphorylation
increased significantly for the first 6 months, decreased
significantly from 6 –12 months, increased significantly
from 12–18 months, and then remained stable until the end
of the study (Fig. 5A). In contrast, phosphorylation of
IRS-1 in the E group increased significantly until the end
of the study. Phosphorylation of IRS-1 was significantly
greater in the E group than in the other groups at 12, 18,
and 24 months and significantly higher in the C group than
in the OVX group at 0, 18, and 24 months.
In the diencephalon, the patterns of tyrosine phosphor-
ylation of IRS-1 were similar to those observed in the
cortex in the C and E groups (Fig. 5B). In contrast, in the
OVX group, phosphorylation of IRS-1 decreased signifi-
cantly from the start to the end of the study. In the dien-
cephalon, the phosphorylation of IRS-1 was significantly
greater in the C group than in the other groups, except at
12 months. In addition, phosphorylation of IRS-1 was sig-
nificantly higher in the E group than in the OVX group,
except at 6 months.
The interaction between ER and the p85 subunit of
PI3-k was also studied. Interestingly, an ER67-p85 in-
teraction was detected in the cortex and diencephalon in
the C group but not in the OVX and E groups (Fig. 6, A and
B). In the cortex of the C group, the ER67-p85 and
ER46-p85 interactions showed a similar pattern; there
was a significant increase until 6 months and a significant
decrease from 6 –12 months, and then the interactions re-
mained stable until the end of the study (Fig. 6A). In the
OVX group, the ER46-p85 interaction decreased signif-
icantly over the first 6 months, followed by a significant
increase from 6 months to the end of the study. In the
cortex of rats in the E group, the ER46-p85 interaction
increased significantly from 6 months to the end of the
study. The ER46-p85 interaction was always signifi-
cantly greater in the C group than in the other groups and
was always significantly lower in the OVX group than in
the other groups, except at the beginning of the study.
In the diencephalon, both the ER67-p85 and the
ER46-p85 interaction showed similar patterns in the C
group: there was a significant increase over the first 12
months, followed by a significant decrease toward the end
of the study (Fig. 6B). In the OVX group, there was a
significant decrease in the ER46-p85 interaction until
the 24-month time point, whereas the opposite was found
in the E group. The ER46-p85 interaction was always
significantly greater in the C group than in the other
groups and was always significantly lower in the OVX
group than in the other groups, except at 6 months.
Changes in the level of phosphorylation of IRS-1 indi-
cate that activation of the intracellular IRS-1 pathways is
involved in aging. Therefore, the interaction between the
p85 subunit of PI3-k and IRS-1 was studied. In the cortex,
this interaction increased significantly for the first 6
months and then decreased significantly from 6 –24
months in the C group (Fig. 7A). A similar pattern was
observed in the OVX group. However, in the E group,
IRS-1 phosphorylation levels decreased significantly from
6 –12 months and then increased significantly from 12
months to the end of the study. At 6 and 24 months, the
p85-IRS-1 interaction was significantly greater in the E
FIG. 4. Association between ER and IRS-1 in cortex (panel A) from intact (C) (ER67: F(4,34)  1078.0; P  0.0001; ER46: F(4,34)  5545.0;
P 0.0001), ovariectomized (OVX) (ER67: F(4,34) 7656.6; P 0.0001; ER46: F(4,34) 100,697.2; P 0.0001), and estradiol-treated (E) rats
(ER67: F(4,34) 401.6; P 0.0001; ER46: F(4,34) 482.7; P 0.0001) at 0 (ER67: t(12,0.05) 0.74; P nonsignificant; ER46: t(12,0.05) 5.69;
P 0.05), 6 (ER67: F(2,20) 801.3; P 0.0001; ER46: F(2,20) 26,846.5; P 0.0001), 12 (ER67: F(2,20) 1209.0; P 0.0001; ER46: F(2,20)
28,380.1; P 0.0001), 18 (ER67: F(2,20) 2458.1; P 0.0001; ER46: F(2,20) 1042.6; P 0.0001), and 24 (ER67: F(2,20) 1802.6; P 0.0001;
ER46: F(2,20)  761.9; P  0.0001) months of age and in diencephalon (panel B) from intact (C) (ER67: F(4,34) 1079.9; P  0.0001; ER46:
F(4,34)  1626.7; P  0.0001), ovariectomized (OVX) (ER67: F(4,34)  72,360.9; P  0.0001; ER46: F(4,34)  8399.9; P  0.0001), and
estradiol-treated (E) rats (ER67: F(4,34) 5905.3; P 0.0001; ER46: F(4,34) 361.5; P 0.0001) at 0 (ER67: t(12,0.05) 6.22; P 0.05; ER46:
t(12,0.05) 5.72; P 0.05), 6 (ER67: F(2,20) 7705.1; P 0.0001; ER46: F(2,20) 11,575.5; P 0.0001), 12 (ER67: F(2,20) 4037.3; P 0.0001;
ER46: F(2,20)  19,505.2; P  0.0001), 18 (ER67: F(2,20)  171.3; P  0.0001; ER46: F(2,20)  688.7; P  0.0001), and 24 (ER67: F(2,20) 
36.17;P 0.0001; ER46: F(2,20) 9033.8;P 0.0001)months of age. IRS-1was immunoprecipitated from total lysates as described inMaterials
and Methods. The immunocomplexes were separated using SDS-PAGE and probed with an antibody against ER. The histogram shows the
densitometric analysis of the Western blots. Values are means  SEM (n  7), and represented as the percentage of control values (rats of 0
month from group C). Only significant differences are shown. Statistical significance is based on analysis of pooled raw data using the Tukey
HSD. *, Month vs. next month; a, C vs. OVX, E; b, OVX vs. E; c, OVX vs. C, E; d, OVX vs. C.
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group than in the others, whereas at 12 and 18 months, it
was significantly greater in the C group than in the others.
In the diencephalon, the p85-IRS-1 interaction decreased
significantly in the C group throughout the experiment (Fig.
7B). In the OVX group, this interaction decreased signifi-
cantly from 6 months to the end of the study, whereas in the
E group, it decreased significantly until 12 months and then
increased significantly from 12–24 months. At 6 and 24
months, the p85-IRS-1 interaction in the diencephalon was
significantly greater in the E group than in the others,
whereas at 12 and 18 months, it was significantly greater in
the C group than in the others.
FIG. 5. IRS-1 tyrosine phosphorylation
in cortex (panel A) from intact (C)
(F(4,34)  1510.4; P  0.0001), ovariecto-
mized (OVX) (F(4,34)326.2;P0.0001),
and estradiol-treated (E) rats (F(4,34) 
1522.5; P  0.0001) at 0 (t(12,0.05)  7.39;
P 0.05), 6 (F(2,20) 720.2; P 0.0001),
12 (F(2,20)  447.5; P  0.0001), 18
(F(2,20)  3296.6; P  0.0001), and 24
(F(2,20)  3084.6; P  0.0001) months of
age and in diencephalon (panel B) from
intact (C) (F(4,34)  595.2; P  0.0001),
ovariectomized (OVX) (F(4,34) 12,146.5;
P  0.0001), and estradiol-treated (E)
rats (F(4,34)  749.2; P  0.0001) at 0
(t(12,0.05)  0.65; P  nonsignificant), 6
(F(2,20)1806.1;P0.0001), 12 (F(2,20)
623.0;P0.0001), 18 (F(2,20)581.7;P
0.0001), and 24 (F(2,20)  5094.3; P 
0.0001) months of age. IRS-1 was immu-
noprecipitated from total lysates as de-
scribed in Materials and Methods. The
immunocomplexes were separated using
SDS-PAGE and probed with an antibody
against phosphotyrosine. The histogram
shows the densitometric analysis of the
Western blots. Values are means  SEM
(n  7), and represented as the percent-
ageof control values (rats of 0month from
groupC). Only significant differences are
shown. Statistical significance is based
on analysis of pooled raw data using the
Tukey HSD. *, Month vs. next month; a,
C vs. OVX, E; b, OVX vs. E; c, OVX vs. C,
E; d, OVX vs. C; e, E vs. OVX, C.
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FIG. 6. Association between ER and
p85 subunit of PI3-k in cortex (panel A)
from intact (C) (ER67: F(4,34) 1565.3;
P  0.0001; ER46: F(4,34)  19,871.7;
P  0.0001), ovariectomized (OVX)
(ER46: F(4,34) 26,940.6; P 0.0001),
and estradiol-treated (E) rats (ER46:
F(4,34)  4537.9; P  0.0001) at 0
(ER46: t(12,0.05)  3.62; P  0.05), 6
(ER46: F(2,20) 80,230.9; P 0.0001),
12 (ER46: F(2,20)  19,215.8; P 
0.0001), 18 (ER46: F(2,20)  35,475.1;
P  0.0001), and 24 (ER46: F(2,20) 
3978.5; P  0.0001) months of age and
in diencephalon (panel B) from intact
(C) (ER67: F(4,34) 2469.2;P 0.0001;
ER46: F(4,34)  8090.2; P  0.0001),
ovariectomized (OVX) (ER46: F(4,34)
7242.1; P  0.0001), and estradiol-
treated (E) rats (ER46: F(4,34) 498.8;
P 0.0001) at 0 (ER46: t(12,0.05) 0.64;
P nonsignificant), 6 (ER46: F(2,20)
6697.5; P  0.0001), 12 (ER46:
F(2,20)  25,695.6; P  0.0001), 18
(ER46: F(2,20)  4915.8; P  0.0001),
and 24 (ER46: F(2,20)  5003.4; P 
0.0001) months of age. p85 subunit of
PI3-k was immunoprecipitated from to-
tal lysates as described in Materials
and Methods. The immunocomplexes
were separated using SDS-PAGE and
probed with an antibody against ER.
The histogram shows the densitometric
analysis of the Western blots. Values
are means  SEM (n  7) and repre-
sented as the percentage of control val-
ues (rats of 0month fromgroupC). Only
significant differences are shown. Sta-
tistical significance is based on analysis
of pooled raw data using the Tukey
HSD. *, Month vs. next month; a, C vs.
OVX, E; b, OVX vs. E; d, OVX vs. C.
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FIG. 7. Associationbetweenp85subunitof
PI3-k and IRS-1 in cortex (panel A) from
intact (C) (F(4,34)  2809.7; P  0.0001),
ovariectomized (OVX) (F(4,34)  11,601.7;
P 0.0001), and estradiol-treated (E) rats
(F(4,34) 71,971.7; P  0.0001) at 0
(t(12,0.05)  0.53; P  nonsignificant), 6
(F(2,20) 5312.4; P 0.0001), 12 (F(2,20)
8209.9; P  0.0001), 18 (F(2,20)  2241.9;
P 0.0001), and 24 (F(2,20)  4502.0; P
0.0001)months of age and in diencephalon
(panel B) from intact (C) (F(4,34)  650.9;
P  0.0001), ovariectomized (OVX)
(F(4,34)4523.8;P0.0001),andestradiol-
treated (E) rats (F(4,34)  5671.3; P 
0.0001) at 0 (t(12,0.05)  0.44; P  nonsig-
nificant),6 (F(2,20)3846.2;P0.0001),12
(F(2,20) 1931.7; P 0.0001), 18 (F(2,20)
405.8;P0.0001), and24 (F(2,20)1682.2;
P 0.0001) months of age. IRS-1 was im-
munoprecipitated from total lysates as de-
scribed inMaterials andMethods. The im-
munocomplexes were separated using
SDS-PAGE and probed with an antibody
against phosphotyrosine. The histogram
shows the densitometric analysis of the
Western blots. Values are means  SEM
(n 7) and represented as the percentage
of control values (rats of 0 month from
group C). Only significant differences are
shown. Statistical significance is based on
analysis of pooled raw data using the
TukeyHSD. *,Month vs. nextmonth; a, C
vs. OVX, E; b, OVX vs. E.
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Finally, the estrogen receptor levels in total crude ex-
tracts from the cortex and diencephalon were studied us-
ing an MC-20 antibody, as previously described (31–34).
This technique detects amino acids 580 –599 of the ligand-
binding domain of ER but does not recognize ER. Two
immunoreactive bands of approximately 67 and 46 kDa
were identified in both regions of the brain. It was found
that aging and/or estradiol treatment can change ER
expression levels. In the cortex, ER67 increased signifi-
cantly for the first 6 months and then decreased signifi-
cantly from 6 –24 months in the C group, whereas ER46
increased significantly for 6 months, decreased signifi-
cantly from 6 –12 months, and then remained stable until
the end of the study (Fig. 8A). The pattern was different
in the OVX group; both ER isoforms decreased signifi-
cantly throughout the experiment. In the E group, both
isoforms showed a significant decrease from 6 –12 months,
followed by a significant increase to the end of the study.
Both ER isoforms were always significantly greater in the
C group than in the other groups and significantly lower
in the OVX group than in the other groups, except for
ER67 at 12 months.
In the diencephalon region, ER67 increased signifi-
cantly in the C group until the 12-month time point and
then decreased significantly to the end of the study (Fig.
8B). However, in the OVX and E groups, ER67 decreased
significantly from the start to the end of the study. In the
C group, no significant changes were observed in ER46
for the first 18 months, after which there was a significant
decrease to 24 months, whereas there was a significant
decrease in ER46 from the start to the end of the study
in the other groups. The level of ER67 was significantly
greater in the E group than in the other groups except at
6 months and was significantly lower in the OVX group
than in the other groups except at 6 months. ER46 was
greater in the C group than in the other groups throughout
the study and was always significantly lower in the OVX
group than in the other groups.
Discussion
Several previous studies have shown that adult rats are a
suitable animal model for studying the onset of aging (35, 36).
As early as 6 months of age, rats begin to display signs of
age-induced metabolic disturbances (37, 38). In addition, the
prevalence of impaired glucose tolerance and type 2 diabetes
mellitus has been shown to increase with age in both humans
(39) and rats (37). It has been demonstrated clearly in both
clinical and experimental studies that diabetes mellitus (type
1 and type 2) is an increasingly common disorder associated
with several CNS complications (40, 41). Various studies
have shown that estradiol administration in postmenopausal
females has positive effects not only on the CNS but also on
glucose homeostasis (5, 26, 28, 42–46). Taken together, these
observations indicate that treatment with estradiol may be
able to prevent age-related insulin resistance and neurode-
generative diseases. However, studies that have investigated
the beneficial effects of low-dose 17-estradiol on glucose
homeostasis have shown that estradiol treatment does not
prevent the impairments in memory and learning that are
associated with the aging process (26). Despite the previous
findings reported by our laboratory, we hypothesize, as do
others (5, 43), that low doses of estradiol could improve some
aspects of brain function that are impaired with aging.
Glucose is the primary energy source for the brain. It has
been shown that Glut-3 and Glut-4 are coexpressed in the
rat (47) and primate (25) brains; however, the significance
of this finding is not fully understood. The first step in the
present study was to determine the changes in Glut-3 and
Glut-4 levels that occurred in our experimental model.
Interestingly, in both brain regions that were studied, the
aging process reduced the Glut-3 and Glut-4 levels from
12 months onwards, as seen in the C group (Figs. 3 and 4).
This inflection point coincides with the time at which all
intact animals showed irregular cycling, mainly a persis-
tent diestrous phase. Therefore, it could be considered that
this point marks the onset of a gradual decline in regular
estrous cyclicity, which is associated with a gradual im-
pairment in ovulatory function and altered patterns of
steroid secretion (48 –50). It is also probably associated
with a gradual impairment in brain homeostasis, as shown
by data that demonstrate changes in the glucose transporters.
To the best of our knowledge, this is the first paper to
show the long-term effect of ovariectomy on Glut-3 and
Glut-4 levels in the rat brain. Clearly, ovariectomy reduced
the level of Glut-3 in both brain regions from 6 months
when compared with the level in control animals (Fig. 2,
A and B). Moreover, the decreased Glut-3 level was as-
sociated with the aging process, because the levels of this
glucose transporter decreased significantly from 12
months in the cortex and from 6 months in the dienceph-
alon. Glut-3 is one of the main glucose transporters and is
responsible for most of the glucose uptake and utilization
in the brain. Thus, early loss of ovarian function may
increase the effects of aging on the brain in relation to
glucose uptake and utilization. The Glut-4 levels observed
in the diencephalon of the OVX group (Fig. 3B) were
similar to the Glut-3 levels; therefore, if Glut-4 is an al-
ternative glucose transporter in the brain, the combined
effects of aging and early ovariectomy are similar. How-
ever, neither aging nor ovariectomy had any effect on
Glut-4 levels in the cortex of OVX rats until 18 months after
ovariectomy (Fig. 3A); at 12 months, the Glut-4 level in the
OVX group was significantly higher than in the C group.
Therefore, ovarian hormones do not appear to be involved
in controlling Glut-4 levels in the cortex of middle-aged
rats. The aging process, which occurs between 18 and 24
months in the rat, appears to have more important con-
sequences on Glut-4 levels in the cortex. Currently, there
is no convincing explanation for this finding.
Compared with those in the OVX group, the levels of
both transporters markedly increased in the group treated
with estradiol, except for the Glut-4 level in the cortex at
6 and 12 months. It is likely that the expression rate of the
Glut-4 gene is down-regulated by estradiol. Progesterone
may regulate the role of estradiol, based on the results seen
in the C group, and the absence of both hormones implies
the loss of Glut-4 gene regulation, as occurred in the OVX
group. Given these results, the estradiol-induced increase
in the expression of glucose transporters may improve
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FIG. 8. ER in cortex (panel A) from
intact (C) (ER67: F(4,34)  141,550.4;
P  0.0001; ER46: F(4,34)  38,307.8;
P  0.0001), ovariectomized (OVX)
(ER67: F(4,34)  720.3; P  0.0001;
ER46: F(4,34)  2312.8; P  0.0001),
and estradiol-treated (E) rats (ER67:
F(4,34)  12,902.5; P  0.0001; ER46:
F(4,34)  13,561.7; P  0.0001) at 0
(ER67: t(12,0.05)  3.56; P  0.05;
ER46: t(12,0.05)  4.52; P  0.05), 6
(ER67: F(2,20) 78,453.8; P 0.0001;
ER46: F(2,20)  4298.7; P  0.0001),
12 (ER67: F(2,20)  150,982.3; P 
0.0001; ER46: F(2,20)  753,978.4;
P  0.0001), 18 (ER67: F(2,20) 
731,066.9; P  0.0001; ER46:
F(2,20)  129,222.7; P  0.0001), and
24 (ER67: F(2,20)  67,316.5; P 
0.0001; ER46: F(2,20)  45,450.0; P 
0.0001) months of age and in dien-
cephalon (panel B) from intact (C)
(ER67: F(4,34)  1993.3; P  0.0001;
ER46: F(4,34)  4552.3; P  0.0001),
ovariectomized (OVX) (ER67:
F(4,34)  6201.7; P  0.0001; ER46:
F(4,34)  155.7; P  0.0001), and es-
tradiol-treated (E) rats (ER67:
F(4,34)  3918.2; P  0.0001; ER46:
F(4,34)  8914.6; P  0.0001) at 0
(ER67: t(12,0.05)  51.54; P  0.05;
ER46: t(12,0.05)  1.02; P  nonsig-
nificant), 6 (ER67: F(2,20)  25,334.1;
P  0.0001; ER46: F(2,20)  3745.4;
P  0.0001), 12 (ER67: F(2,20) 
3470.1; P  0.0001; ER46: F(2,20) 
8122.5; P  0.0001), 18 (ER67:
F(2,20)  1042.4; P  0.0001; ER46:
F(2,20)  28,884.6; P  0.0001), and 24
(ER67: F(2,20) 14,285.5; P 0.0001;
ER46: F(2,20)  5332.4; P  0.0001)
months of age. The histogram shows
the densitometric analysis of the
Western blots. Values are means 
SEM (n  7) and represented as the
percentage of control values (rats of 0
month from group C). Only significant
differences are shown. Statistical sig-
nificance is based on analysis of pooled
raw data using the Tukey HSD. *,
Month vs. next month; a, C vs.OVX, E;
b, OVX vs. E; d, OVX vs. C; e, E vs.
OVX, C.
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brain glucose utilization and preserve brain function (20,
25). The results suggest that low doses of 17-estradiol
could have positive effects on rat neuronal homeostasis
and could slow the progressive loss of glucose transport-
ers that is associated with ovariectomy. It is very impor-
tant to note that when the results from the E group were
compared with those from the control group, the apparent
amelioration of the effects of normal aging due to hor-
monal treatment were noticeable only in the cortex. Cur-
rently, there is no acceptable explanation for this finding,
but it could have clinical relevance, because the rates of
brain glucose transport and utilization are markedly re-
duced in elderly and diabetic patients (22). Conversely,
because Glut-4 immunoreactivity has been observed in an
intracellular localization, this glucose transporter could be
translocated to the plasma membrane; this translocation
phenomenon could be controlled by metabolic and/or
hormonal parameters (for a review, see Ref. 51). Depend-
ing on the glycemia achieved during the hyperinsulinemic
clamp, glucose uptake could be either increased or de-
creased in different brain areas (51). This could reasonably
explain the different results observed for the Glut-4 levels
in the cortex and the diencephalon of the various exper-
imental groups in the current study (Fig. 3, A and B). The
exact physiological role of Glut-4 in the brain is currently
unknown; however, various hypotheses have been pro-
posed; Glut-4 may provide additional glucose uptake in
different brain areas or may be involved in glucose-sens-
ing mechanisms (for a review, see Ref. 51). More investi-
gations are needed to determine the role of estradiol in the
control of brain Glut-4 levels, the physiological impor-
tance of estradiol in this role, and the possible relevance
of this information to a better understanding of the effects
of aging in the female brain.
Several studies have suggested that the molecular mech-
anism by which estradiol exerts its neuroprotective effects
involves activation of the PI3-k signaling pathway (5, 9, 10,
14, 15, 52, 53). Studies have found that only high phar-
macological doses of estradiol are responsible for neuro-
protection (7) and activation of the PI3-k signaling path-
way (9, 10). Interestingly, several studies have indicated
that the improvement in insulin resistance not only im-
proves peripheral glucose homeostasis but also improves
diabetes-related CNS complications (40, 41). Our previous
results have demonstrated that low-dose 17-estradiol
does not appear to ameliorate age-related effects on learn-
ing and memory (26); however, it was found that low-dose
17-estradiol improved age-related insulin resistance in
ovariectomized rats. Therefore, it is possible that our es-
tradiol treatment model could be used to demonstrate
improvements in brain homeostasis, despite our previous
results on learning and memory.
ER has been implicated in the activation of the PI3-k
signaling pathway (9, 10, 14, 15), which includes key mol-
ecules of the intracellular insulin/IGF-I pathway such as
IRS-1 and the p85 subunit of PI3-k. Therefore, the inter-
actions of ER with IRS-1 and p85 were characterized. In
both regions of the brain studied here, SDS-PAGE showed
two immunoreactive bands associated with IRS-1 (Fig. 4).
Given their molecular masses, as indicated by SDS-PAGE,
these were named ER67 and ER46. The existence of
these two isoforms of ER has been previously described
(31, 33, 34, 41, 54, 55). Interestingly, an age-related reduc-
tion in the association between ER67 and IRS-1 was found
in both brain regions of all groups of rats in this study (Fig.
4, A and B). Therefore, 17-estradiol treatment does not
seem to prevent the age-related decrease in the ER67-
IRS-1 interaction. Compared with the C group, the ovari-
ectomized group showed a decrease in this interaction
within the cortex, and 17-estradiol treatment did not
appear to alter this finding. However, the opposite was
found in the diencephalon, at least until the 12-month time
point. Therefore, these results appear to support the hy-
pothesis that progesterone has an important role in reg-
ulating the ER67-IRS-1 interaction. More studies are re-
quired to fully investigate this issue.
In the OVX and C groups, the ER46-IRS-1 interaction
was reduced during aging in both regions of the brain that
were studied, whereas estradiol treatment prevented this
reduction (Fig. 4, A and B). Compared with the C group,
the OVX group showed a clear reduction in this interac-
tion. In the E group, estradiol treatment significantly in-
creased this interaction compared with the OVX group.
Therefore, these results suggest that estradiol controls the
ER46-IRS-1 interaction and appears to prevent not only
the effects of ovariectomy but also the effects of the aging
process.
In contrast, no interaction was detected between ER67
and p85 in the OVX and E groups in the two regions of the
brain that were studied (Fig. 6, A and B). However, this
interaction was detected in the control group, which
showed a significant decrease in the interaction at the end
of the study (24 months) in both regions of the brain.
Therefore, the ER67-p85 interaction appears not to be
exclusively controlled by estradiol; progesterone probably
has an important role in the regulation of the ER67-p85
interaction in the brain. More research is needed to prove
this assumption.
Interestingly, compared with the C group, ovariecto-
mized rats showed a reduced interaction between ER46
and p85 (Fig. 6, A and B), and estradiol treatment only
partially reversed this effect in both brain regions. Estra-
diol treatment appears to up-regulate this interaction dur-
ing aging. The most important consequence of this effect
is that it is related to an increase in the tyrosine phos-
phorylation rate of IRS-1, which was observed in the E
group during the aging process (Fig. 5, A and B). We
hypothesize that the neuroprotective properties classically
ascribed to estradiol depend on the control of the ER46-
p85 interaction. ER46 acts as an activation function-1
(AF-1) competitive inhibitor of ER67, due, in part, to its
ability to out-compete ER67 for binding to estrogen re-
ceptors (54). It is also possible that, compared with ER67,
ER46 has different binding affinities for coactivators or
corepressors; this could also play a role in the interplay
between these two isoforms and their interactions with
different promoters. Moreover, estradiol was shown to
down-regulate the level of ER67 (56, 57). Therefore, it is
conceivable that some actions of estradiol depend on the
ER67/ER46 ratio through the control of ER67 expres-
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sion or stability (58). The present results suggest that the
low ER67/ER46 ratio favors the ER46-p85 interaction
and could increase the neuroprotective effects of estradiol.
Finally, the interaction between the p85 subunit of
PI3-k and IRS-1 was examined, because this interaction
could play an important role in the molecular mechanism
by which estradiol exerts its neuroprotective effects via
activation of the IRS-1-PI3-k pathway (5, 9, 10, 14, 15).
Figure 7, A and B, shows that during the normal aging
process in intact rats (group C), there was a significant
decrease in this interaction in both brain areas at the end
of the study period (24 months; similar results were ob-
tained in the OVX group). The early loss of ovarian func-
tion increased the effects of aging, because at 6 months in
the cortex and at 12 months in the diencephalon, the in-
teraction was significantly lower in the OVX group than in
the C group. In contrast, estradiol treatment appeared to
significantly increase this interaction in both brain regions
from 12–24 months (Fig. 7, A and B). Estradiol treatment
not only prevented the effects of ovariectomy in relation
to the IRS-1-p85 interaction, but this interaction was also
significantly higher in the E group than in the C group at
24 months in both regions of the brain. This appears to
indicate that the increase in phosphorylation of IRS-1 ob-
served in the E group from 6 months (Fig. 5, A and B),
which was probably induced by estradiol, reflects func-
tional activation of the IRS-1 signaling pathway. There-
fore, the effect of estradiol on the interaction between p85
and IRS-1 indicates that estradiol may regulate this sig-
naling pathway in the brain. This observation supports the
theory that we have, to the best of our knowledge, pro-
posed for the first time in this paper.
Other ligands may activate IRS-1/PI3-k pathways in the
brain. In particular, IGF-I seems to be particularly impor-
tant in the process of neuroprotection; it can reverse age-
related effects (59) and attenuate the age-related decrease
in cerebral glucose utilization (60). Moreover, gonadal
hormones have been found to regulate the expression of
IGF-I receptor mRNA and IGF-I-binding protein mRNA in
adult female rat brains (61, 62). Several studies have shown
that low doses of 17-estradiol increase IGF-I binding in
the brain by significantly increasing the numbers of IGF-I
receptors (63). Therefore, it seems clear that the interaction
of both systems plays a role in the prevention of neuronal
age-related effects (64). The neuroprotective effect of es-
tradiol is abolished by PI3-k inhibitors (65); this indicates
that PI3-k has a role in estradiol-mediated neuroprotection
and may be involved in the IGF-I receptor pathway, which
is known to be activated by ER but not by ER (66). After
systemic administration of estradiol to adult ovariecto-
mized rats, there is a transient increase in tyrosine phos-
phorylation of the IGF-I receptor in the brain, transient
interaction of the IGF-I receptor with ER but not with
ER, and enhanced interaction of ER with p85 (15).
These findings suggest that by interacting with some com-
ponents of the IGF-I signaling pathway, ER affects the
actions of IGF-I in the brain. These findings suggest future
avenues of research.
However, interesting questions remain. The findings of
the present study do not explain whether the increased
interaction between ER and IRS-1 in turn increases the
p85-IRS-1 interaction or whether the ER-IRS-1 and ER-
p85 interactions are necessary to facilitate the p85-IRS-1
interaction. It is not known whether the interactions be-
tween ER and IRS-1 and p85 occur sequentially or
whether ER binds to a multimolecular complex of IRS-1
and PI3-k. Mendez et al. (15) also studied this issue. They
questioned whether the ER that interacts with this sig-
naling pathway is localized in the cytoplasm or is asso-
ciated with specific membrane domains, such as caveolae
(67). In the present study, only some of the components
that may be involved in the neuroprotective effect of es-
tradiol were investigated. The effects of other important
molecules, such as Akt, MAPK, and glycogen synthase
kinase 3 (9, 10, 68, 69), which were not studied, should be
investigated using our experimental animal model to fully
understand the neuroprotective role of estradiol.
In this paper, the changes in ER and its interactions
with several proteins involved in the PI3-k pathway were
studied because it has been shown, with respect to the
neuroprotective effects of estradiol, that ER, but not ER,
plays a critical role in the treatment and prevention of
neural dysfunction that is associated with normal aging or
brain injury (13). Our results clearly show that normal
aging (group C) was associated with a decrease in both
ER isoforms in both of the brain regions that were studied
(Fig. 8, A and B) and that ovariectomy aggravates the
effects of normal aging, as has already been extensively
documented. However, although it was thought that es-
tradiol treatment would reverse the effects of ovariectomy,
this was observed only with respect to ER67 in the di-
encephalon (Fig. 8B). Our results clearly show that 17-
estradiol treatment prevented the effects of ovariectomy
on both ER isoforms. The expectations for estradiol treat-
ment were based on the results related to Glut-3 and Glut-4
levels in the cortex (Figs. 2A and 3A, respectively), the
ER-IRS-1 interaction (Fig. 4, A and B), and the ER46-
p85 interaction (Fig. 6, A and B); these data appear to
suggest that ER46 could be the estradiol-modulated iso-
form of ER that is responsible for the mediation of the
neuroprotective effects of estradiol. However, the results
shown in Fig. 8, A and B, raise some doubts about the role
of ER46. It is necessary to further explore the idea that the
key to the neuroprotective effects of estradiol is related to
the ER67/ER46 ratio and that this ratio depends on the
region of the brain that is studied and/or the estradiol
doses used.
In summary, our findings indicate that 17-estradiol
treatment during aging in ovariectomized rats may acti-
vate the IRS-1 signaling pathway, thereby increasing the
tyrosine phosphorylation of IRS-1 and the interaction be-
tween the p85 subunit of PI3-k and IRS-1. Moreover,
17-estradiol treatment appears only to control the inter-
actions that involve the ER46 isoform. During aging,
17-estradiol treatment may improve some aspects of neu-
ronal homeostasis, because the levels of expression of the
glucose transporters in both regions of the brain of estra-
diol-treated rats were significantly increased compared
with the control group. However, more studies are re-
quired to clarify the neuroprotective role of estradiol in
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relation to the other important molecules involved in the
IRS-1-PI3-k signaling pathway.
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